As mega-cap technology equities experience volatility after a prolonged bull market, institutional portfolio managers are actively executing sector rotation strategies. The search for yield and defensive growth has led prominent market commentators, including CNBC’s Mad Money host Jim Cramer, to highlight pharmaceutical giants as key alternatives. Cramer classifies these innovators as “non-tech tech stocks”—businesses that leverage cutting-edge biotechnology to generate tech-like growth while providing defensive insulation during market downturns.
The Case for Eli Lilly (LLY) and Johnson & Johnson (JNJ)
According to Cramer, Eli Lilly and Company (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) represent premier vehicles for capturing innovation outside the traditional silicon valley ecosystem. Both enterprises reported strong quarterly earnings, demonstrating robust fundamental execution. Eli Lilly continues to benefit from its market-leading GLP-1 weight-loss and diabetes franchise, driving its forward price-to-earnings (P/E) ratio to a premium 32.7x. Conversely, Johnson & Johnson offers a highly stable balance sheet and steady dividend distributions, trading at a more conservative forward P/E of 22.27x. Institutional interest remains strong; during Q1 2026, LLY led the sector with 132 hedge fund positions, while JNJ saw its hedge fund backing increase to 113 positions.
Biotech Innovation Beyond the Mega-Caps
Other healthcare operators are also proving that clinical success translates directly to equity appreciation. Amgen Inc. (NASDAQ: AMGN) posted an excellent quarter, trading at 18.35x forward earnings with 65 hedge fund positions in Q1 2026. Meanwhile, Moderna (NASDAQ: MRNA) secured FDA approval for its mRNA flu vaccine, illustrating the commercial viability of its specialized pipeline and supporting a massive 83% year-to-date rally. Short interest across these core holdings remains exceptionally low, with LLY at 1.15%, JNJ at 1.27%, and AMGN at 2.38% of float.
Why Bristol-Myers Squibb (BMY) Faces Headwinds
Despite a high dividend yield of 3.9% and a low valuation multiple of 9.38x forward earnings, Bristol-Myers Squibb Company (NYSE: BMY) has drawn caution. While rumors circulated of a preliminary acquisition bid by AstraZeneca, Wall Street analysts remain skeptical. RBC analyst Trung Huynh noted that BMY’s impending patent cliff—the period when key drugs lose exclusivity protection—makes valuation agreement difficult. TD Cowen analyst Steve Scala also warned that BMY’s patent exposure could dilute AstraZeneca’s long-term sales growth profile, prompting Cramer to recommend trimming BMY positions in favor of JNJ.
Frequently Asked Questions
What is a “non-tech tech stock” in market terminology?
This term describes companies outside the traditional technology sector (such as healthcare or industrial firms) that utilize proprietary research, advanced biotechnology, or engineering to achieve high growth margins similar to tech companies.
What is a patent cliff in the pharmaceutical industry?
A patent cliff refers to the abrupt drop in sales a pharmaceutical company experiences when the patent protection on its major revenue-producing drugs expires, allowing cheaper generic competitors to enter the market.
Why does Eli Lilly (LLY) trade at a higher valuation multiple than JNJ and BMY?
Eli Lilly trades at a premium forward P/E of 32.7x due to high market demand for its GLP-1 treatments. Investors are willing to pay a premium for LLY’s projected earnings growth compared to JNJ’s stable profile or BMY’s patent risks.
